Form 4: Organon & Co. Executive Kirke Weaver Reports Stock Transactions

Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reports the vesting and disposal of restricted stock units and common stock transactions on May 4, 2024.

Summary

• On May 4, 2024, Kirke Weaver, General Counsel & Corporate Secretary of Organon & Co., reported transactions involving Organon & Co. common stock.
• Weaver vested 1,248 restricted stock units (RSUs) which converted into common stock.
• Weaver disposed of 356 shares of common stock at a price of $19.61 per share to cover tax obligations.
• Following these transactions, Weaver directly owns 29,160 shares of Organon & Co. common stock.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in financial analysis.
• Comparing Weaver's transactions to those of other executives at Organon and peer companies like Teva or Viatris can provide insights into management's overall sentiment and confidence in the company's prospects.
• The vesting schedule of the RSUs (one-third each year for three years) is a typical vesting arrangement.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they reflect routine executive compensation and tax obligations.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates